Clinical Trials Logo

Clinical Trial Summary

This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone. One year retrospective data and 2 year prospective data will be collected.


Clinical Trial Description

This study is a multicentre, retrospective and prospective observational, cohort design, determining aggregate drug usage patterns and commonly used clinical outcomes associated with the use of long-acting injectable risperidone. The objectives of this study are to collect sufficient retrospective outcome data to allow the evaluation of treatment outcomes with long acting medication compared to previous treatments and to document clinical effectiveness and long-term treatment outcomes in actual practice. Additional objectives are to prospectively assess medication usage patterns and to evaluate reasons for initiation and/or discontinuation of new antipsychotic medications. The study design is a non-interventional, single-arm, observational survey on the use of long-acting injectable risperidone and other long-acting (depot) or oral atypical antipsychotics, with the aim to assess patient outcomes by existing risk or disease factors, patient characteristics, or previous medication. Having reached agreement with the patient on starting treatment with long-acting injectable risperidone, physicians have the opportunity to document the patient's clinical data in the Registry. At baseline, data will be collected retrospectively over a minimum period of 12-months per patient. Data will be collected prospectively over a 24-month period per patient at approximately 3-month intervals after starting treatment. This study will document data of patients for whom treatment with the new antipsychotic medication is indicated, and who are being treated according to the local label. The start date for collecting data is the date the new antipsychotic treatment is initiated, whether as inpatient or outpatient. The preceding 12 months and the next 2 years are respectively for each patient the retrospective and prospective periods of interest. All patients starting with a new antipsychotic medication, decided after agreement between the physician and the patient, in accordance with the local label, are eligible for inclusion in this survey. While patients participating in randomized clinical trials are not excluded, their participation will be noted. Data will be entered by the treating physician. All data collected must be the result of the normal medical care of the patient. No intervention on treatment decisions permitted. The patient's baseline data will be collected within the first week following initiation of the new antipsychotic treatment. Prospective data collection has to occur 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after initiation of the new antipsychotic treatment. If a patient stops the newly initiated antipsychotic treatment the reason for discontinuation has to be reported. Patients discontinuing newly initiated antipsychotic treatment will continue to be followed for up to 24 months. In retrospective period the following treatment outcomes will be assessed: patient characteristics, treatment history with antipsychotics and other concomitant medication, hospitalization history, reason for initiating the new antipsychotic treatment, treatment satisfaction, remission, clinical global impression (CGI-severity), global assessment of functioning (GAF) and clinical deterioration. In prospective period clinical effectiveness will be assessing the following: employment status, remission, treatment satisfaction, CGI-severity, GAF, clinical deterioration, hospitalization, treatment adherence and (serious) adverse events. Long-acting injectable risperidone is flexible dose (25mg to 75mg), intramuscular injection given into gluteus for 24 months ;


Study Design

Observational Model: Case-Only


Related Conditions & MeSH terms


NCT number NCT00294008
Study type Observational
Source Janssen Korea, Ltd., Korea
Contact
Status Completed
Phase Phase 4
Start date December 2004
Completion date June 2009

See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A